<DOC>
	<DOCNO>NCT02791256</DOCNO>
	<brief_summary>This multicenter , open-label , uncontrolled study evaluate efficacy safety increase dose peginterferon alfa-2a ( Pegasys ) participant Genotype 1/4/5/6 CHC early non-response standard course peginterferon alfa-2a plus ribavirin . The study consist screening ( 4 week ) , treatment ( 32 week ) , follow-up ( 24 week ) .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a Plus Ribavirin Early Non-Responder Participants With Chronic Hepatitis C ( CHC ) Genotype 1 , 4 , 5 , 6</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants serologic evidence chronic hepatitis C infection antiHCV antibody test Participants receive first treatment chronic hepatitis C ( i.e . previously naive therapy ) consist peginterferon alfa2a plus ribavirin 16 week ( +/ 10 day ) , without reach negative 2log drop Serum Hepatitis C Virus Ribonucleic Acid ( HCVRNA ) Week 12 therapy compare pretreatment value , must still therapy ( wash ) HCVRNA quantifiable test reporting international unit Compensated liver disease ( ChildPugh Grade A clinical classification ) Participants cirrhosis transition cirrhosis abdominal ultrasound , computerize tomography ( CT ) scan , magnetic resonance imaging ( MRI ) scan without evidence hepatocellular carcinoma serum alpha fetoprotein ( AFP ) less ( &lt; ) 100 nanogram pe milliliter ( ng/mL ) within 6 month study entry Negative urine blood pregnancy test Participants use two form effective contraception treatment 6 month treatment end Able participate comply study restriction Women ongoing pregnancy breast feed male partner woman pregnant Neutrophil count &lt; 1,500 cells/cubic millimeter ( mm^3 ) platelet count &lt; 90,000 cells/mm^3 initiation ongoing treatment regimen ; neutrophil count &lt; 750 cells/mm^3 platelet count &lt; 50,000 cells/mm^3 screening still therapy peginterferon alfa2a plus ribavirin Hemoglobin ( Hgb ) &lt; 12 gram per deciliter ( g/dL ) initiation ongoing treatment regimen ; Hgb &lt; 10 g/dL screening still therapy peginterferon alfa2a plus ribavirin least 12 week Serum creatinine level great ( &gt; ) 1.5 time upper limit normal screen Therapy systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) currently fail Pegasys plus ribavirin combination therapy less equal ( &lt; = ) 6 month prior first dose study drug Positive test hepatitis A immunoglobulin M ( IgM ) antibody ( antiHAV IgM Ab ) , hepatitis B surface antigen ( HBsAg ) , antihepatitis B core IgM antibody ( antiHBc IgM Ab ) , antiHuman Immunodeficiency Virus antibody ( antiHIV Ab ) History evidence medical condition associate chronic liver disease HCV History bleed esophageal varix condition consistent decompensated liver disease , severe psychiatric disease ( especially depression ) , severe seizure disorder , thyroid disease , immunologically mediated disease , chronic pulmonary disease , cardiac disease , major organ transplantation evidence severe illness , malignancy Evidence drug abuse include excessive alcohol consumption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>